Sort
326,823 grants matching “clinical trial”
Administrative Supplement to Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
$13,774,000Steven Kyle Grinspoon · Massachusetts General Hospital · U01 · FY2018 · HL
Cancer Center Support Grant
$13,733,523Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2021 · CA
Cancer Center Support Grant
$13,733,523Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2020 · CA
Cancer Center Support Grant
$13,733,523Selwyn M Vickers · Sloan-Kettering Inst Can Research · P30 · FY2022 · CA
Cancer Center Support Grant
$13,733,523Selwyn M Vickers · Sloan-Kettering Inst Can Research · P30 · FY2023 · CA
HVTN Laboratory Program
$13,724,431Margaret Juliana McElrath · Fred Hutchinson Cancer Research Center · U01 · FY2010 · AI
Production of a Broadly Neutralizing HIV Antibodies
$13,723,802Jason Gall · National Institute Of Allergy And Infectious Diseases · ZIB · FY2023 · AI
Clinical and Translational Science Institute
$13,721,900Harold R Collard · University Of California, San Francisco · UL1 · FY2018 · TR
ON BEHALF OF NIAID-DCR, FACILITATE THE CONDUCT OF TWO, RANDOMIZED TRIALS AS DETAILED BELOW IN I AND II:I. A RANDOMIZED BLINDED CONTROLLED TRIAL OF TH
$13,721,004Beth Baseler · Leidos Biomedical Research, Inc. · N01 · FY2024 · AI
NIAID/DIVISION OF AIDS:CLINICAL SITE AND STUDY MONITORING
$13,717,357Michelle Vargas · Ppd Development Lp · N01 · FY2012 · AI
SPRINT
$13,711,469David M Reboussin · Wake Forest University Health Sciences · N01 · FY2010 · HL
Cancer Center Support Grant
$13,702,133Craig B Thompson · Sloan-Kettering Inst Can Research · P30 · FY2019 · CA
Critical Path Public Private Partnerships
$13,700,000Klaus Romero · Critical Path Institute · U18 · FY2025 · FD
The Ischemia Trial - CCC
$13,681,446Judith S Hochman · New York University School Of Medicine · U01 · FY2015 · HL
COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTER: UNIVERSAL INFLUENZA RESEARCH
$13,681,100Florian Krammer · Icahn School Of Medicine At Mount Sinai · N01 · FY2021 · AI
Development of Human Anti-Influenza Monoclonal Antibodies for Treatment of Flu
$13,677,248Jaap Goudsmit · Janessen Vaccines And Prevention, Bv · N01 · FY2013 · AI
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
$13,655,252Michael David Hughes · Harvard School Of Public Health · UM1 · FY2016 · AI
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)
$13,641,027Michael David Hughes · Harvard School Of Public Health · UM1 · FY2017 · AI
A Randomized, Double-blind, Placebo-Controlled, Parallel-Group, Phase II Study to Evaluate the Safety and Efficacy of CT1812 in Subjects with Mild to Moderate Alzheimerʼs Disease
$13,634,548Anthony O Caggiano · Cognition Therapeutics, Inc. · R01 · FY2021 · AG
Cell-based Immunotherapy Products
$13,633,885Gautam (george) Mitra · Leidos Biomedical Research, Inc. · N02 · FY2024 · CA
HIV Vaccine Research and Development
$13,623,109National Institute Of Allergy And Infectious Diseases · Y01 · FY2015 · AI
BIOD YT
$13,600,000David Heimbrook · Leidos Biomedical Research, Inc. · N01 · FY2013 · CA
The Harvard Clinical and Translational Science Center
$13,590,437Lee Marshall Nadler · Harvard Medical School · UL1 · FY2021 · TR
Pediatric ACTG Coordinating and Operations Center
$13,579,521Social And Scientific Systems, Inc. · U01 · FY2005 · AI
NHGRI/DIR Clinical Support Services
$13,569,970William Gahl · National Human Genome Research Institute · ZID · FY2018 · HG